Synthesis of a Novel, Conformationally Restricted Analog of Tryptophan

Luca Franceschetti, Aaron Garzon-Aburbeh, Mahmoud R. Mahmoud,⁺ Benedetto Natalini and Roberto Pellicciari.*

Istituto di Chimica Farmaceutica e Tecnica Farmaceutica, Università degli Studi di Perugia, Via del Liceo, 1 - 06123 Perugia (Italy)

Key Words: Conformationally restrained tryptophan analog, diazoketone-BF₃· Et₂O catalyzed intramolecular cyclization, cycloalk[b]indolones.


Abstract: The synthesis of a new, conformationally restrained analog of tryptophan, 1,2,3,4-tetrahydro-2-amino-2carboxy-cyclopent[b]indole (5) is described. The key step involves the BF₃ Et_2O catalyzed intramolecular cyclization of α -diazoketone 2b into the 1,2,3,4-tetrahydro-cyclopent[b]indol-2-one (3).

Conformationally restricted aminoacids are actively sought. They can be incorporated in peptides in place of the corresponding aminoacid thus becoming stereochemical probes for bioactive conformations or selective interactions. They can confer improved metabolic stability, increase the binding stability to receptors or exhibit enzyme inhibiting properties.

As a part of a program directed to the preparation and biological evaluation of conformationally restrained analogs of aminoacids ¹ we become interested in the synthesis of cyclic analogs of tryptophan having the aminoacidic moiety relatively fixed in space with respect to the planar indole nucleus. A derivative fulfilling this requisite, 3-amino-1,2,3,4-tetrahydrocarbazole-3-carboxylic acid was reported previously and shown to be a competitive inhibitor of α -chimotrypsin.² We report now the first synthesis of the structurally related, conformationally more restrained 1,2,3,4-tetrahydro-2-amino-2-carboxy-cyclopent[b]indole (5). A survey of the literature revealed that while a variety of methods have been developed for the synthesis of 1-oxo-³ and 3-oxo-1,2,3,4-tetrahydro-cyclopent[b]indole derivatives,^{4,5} 1,2,3,4-tetrahydro-cyclopent[b]indol-2-one (3), key to our synthesis, was still unknown.

⁺ On leave from Chemistry Department, Faculty of Science, Ain Shams University, Abbassia, Cairo, Egypt.


After exploring a number of routes, we discovered that the sequence outlined in Scheme I provided an expeditious solution to the problem.



Scheme 1

(a) : i) PCI_5 , Et_2O ; ii) CH_2N_2 , Et_2O ; (b) : $BF_3 \cdot Et_2O$; (c) : KCN, $(NH_4)_2CO_3$, DMF^-H_2O ; (d) : i. $Ba(OH)_2$; ii. H_2SO_4 ; iii. Dowex 1x 8, 100–200 mesh, AcO^- form.

Accordingly, 3-indoleacetic acid (1) was reacted with phosphorous pentachloride in anhydrous ether at 0 °C for 1 h under vigorous magnetic stirring in a nitrogen atmosphere. The reaction mixture was concentrated and then diluted with cold (0 °C) hexane. After filtration, the resulting solution was cooled at -78 °C to give the acyl chloride 2a ⁶ with 72% yield. When 2a was treated with diazomethane at 0 °C for 16 h, the diazomethylketone 2b was formed with 57% yield. Following treatment of 2b with boron trifluoride etherate in ether at 0 °C for 2.5 h and stirring overnight of the resulting mixture at room temperature gave the desired 1,2,3,4-tetrahydrocyclopent[b]indol-2-one as a sole product in 92% yield. The mechanism, depicted in Scheme II, presumably involves the initial cyclization of 2b leading to the formation of a spiroindolenine which is rapidly unravelled to the corresponding cyclopentenone derivative (3).⁷



Reaction of ketone 3 with potassium cyanide and ammonium carbonate in DMF-water in a bomb at 120 °C for 2 h produced the spirohydantoin ⁸ 4 with 68% yield. Finally, the amino acid 5 was obtained by heating an aqueous solution of 4 and barium hydroxide octahydrate in a bomb at 120 °C for 5 h followed by purification by ion exchange resin chromatography on Dowex 1x8 and elution with 0.3N acetic acid (53% yield). The structure of 5 was confirmed by analytical and spectroscopic data.^{9,10} The application of the sequence $1 \rightarrow 5$ to the preparation of novel, homologous cycloalk[b]indolones, as well as the biological characterization of 5 are currently under way.

REFERENCES AND NOTES

- 1. a) Pellicciari, R.; Natalini, B.; Marinozzi, M.; Chiorri, C.; Lanthorn, T. H.; Monahan, J. B.; Snyder, J. P. In *Excitatory Amino Acids* 1990, Raven Press, Medical and Scientific Publishers,
- New York, 1991, 6, p 405; b) Pellicciari, R.; Natalini, B.; Luneia, R.; Marinozzi, M.; Roberti, M.; Rosato, G. C.; Sadeghpour, B. M.; Snyder, J. P.; Monahan, J. B.; Moroni, F. *Med. Chem. Res.*, (in press).
- 2. Maki, Y.; Masugi, T.; Hiramitsu, T.; Ogiso, T. Chem. Pharm. Bull., 1973, 21, 2460.
- 1,2,3,4-Tetrahydro-cyclopent[b]indol-1-ones have been obtained by: a) DDQ oxidation of cyclopent[b]indole: i. Oikawa, Y.; Yonemitsu, O. J. Org. Chem., 1977, 42, 1213; see also: ii. Rodriguez, G.; Temprano, F.; Esteban-Calderon, C.; Martinez-Ripoll, M.; Garcia Blanco, S. Tetrahedron, 1985, 41, 3823; b) Pd(OAc)₂ catalyzed cyclization of anilinocyclopentenone: Iida, H.; Yuasa, Y.; Kibayashi, C. J. Org. Chem., 1980, 45, 2938.
- 1,2,3,4-Tetrahydro-cyclopent[b]indol-3-ones have been obtained by: a) acid-catalyzed cyclization of cyclopentane-1,2-dione monophenyl-hydrazone: Manske, R. H. F. Can. J. Res., 1931, 4, 591; b) Friedel-Craft reaction of 3-indolylpropionic acid: i. Jennings, K. F. J. Chem. Soc., 1957, 497; ii. Ishizumi, K.; Shioiri, T.; Yamada, S. Chem. Pharm. Bull., 1967, 863; iii. Nagasaka, T.; Ohki, S. Chem. Pharm. Bull., 1977, 3023.
- 5. For a recent paper on the synthesis and applications of cyclopent[b]indolones, see: Bergman, J.; Venemalm, L.; Gogoll, A. *Tetrahedron*, **1990**, *46*(17), 6067.

- 6. Raucher, S.; Brag, B. L.; Lawrence, R. F. J. Am. Chem. Soc., 1987, 109, 442.
- 7. Smith, A. B., III; Dieter, R. K. Tetrahedron, 1981, 37(14), 2407.
- 8. a) Taylor, J. B.; Lewis, J. W.; Jacklin, M. J. Med. Chem., 1970, 13(6), 1226; b) for a general procedure, see: Coker, J. N.; Kohlhase, W. L.; Martens, T. F.; Rogers, A. O.; Allan, G. G. J. Org. Chem., 1962, 27, 3201.
- 9. Selected spectroscopic data for compounds 2b, 3, 4, 5.

2b: ¹H-NMR (CDCl₂) & 3.65 (2H, s, CH₂CO); 5.10 (1H, s, CHN₂); 6.90-7.50 (5H, m, aromatic 's); 8.50 (1H, br s, NH).

3: mp 184-6 °C; ¹H-NMR (CDCl₃) δ 3.30 (2H, s, CH₂); 3.40 (2H, s, CH₂); 6.80-7.30 (5H, m, NH and aromatic 's).

4: mp 281-2 °C; ¹H-NMR (CDCl₃ + CD₃OD, 9:1) δ 3.06 and 3.40 (2H, 2d, J= 14.8 Hz, CH₂); 3.10 and 3.50 (2H, 2d, J= 16.3 Hz, CH₂); 7.05 and 7.35 (4H, 2m, aromatic 's); ¹³C-NMR (CD₃OD) δ 39.57; 39.87; 74.96; 113.68; 116.39; 120.05; 121.21; 122.71; 126.43; 140.74; 143.92; 159.83; 181.52.

5: mp 170 °C (d); ¹H-NMR (D₂O) δ 3.07 and 3.45 (2H, 2d, J= 15.9 Hz, CH₂); 3.13 and 3.58 (2H, 2d, J= 17.3 Hz, CH₂); 7.05 and 7.38 (4H, 2m, aromatic 's); ¹³C-NMR (CD₃OD) δ 37.54; 37.80; 69.94; 112.95; 114.59; 119.09; 120.49; 122.17; 125.16; 139.10; 143.34; 173.40.

10. Chiral thin layer chromatography (Chiralplate, Macherey-Nagel art. 811057) of 5, performed in MeOH-H₂O-CH₃CN (1:1:4) using 1% aqueous ninhydrin as spraying reagent, reveals the two enantiomeric amino acids as two spots with rf. 0.63 and 0.53, respectively.

(Received in UK 26 January 1993)